Next Article in Journal
Association of Handgrip Strength and Nutritional Status in Non-Dialysis-Dependent Chronic Kidney Disease Patients: Results from the KNOW-CKD Study
Next Article in Special Issue
Correction: Kindlovits et al. Eight Weeks of Intermittent Exercise in Hypoxia, with or without a Low-Carbohydrate Diet, Improves Bone Mass and Functional and Physiological Capacity in Older Adults with Type 2 Diabetes. Nutrients 2024, 16, 1624
Previous Article in Journal
Calcium- and Sodium-Rich Food Intake among Koreans with and without Metabolic Syndrome: Cross-Sectional Analysis of the Korean Genome and Epidemiology Study
Previous Article in Special Issue
Association between Diet Quality and Eating Behavior in Type 2 Diabetes Adults: A Cross-Sectional Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 16
Issue 15
10.3390/nu16152441
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial

by
Metha Yaikwawong
1,
Laddawan Jansarikit
1,
Siwanon Jirawatnotai
1,2,3 and
Somlak Chuengsamarn
4,*
1
Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
2
Siriraj Center of Research Excellence for Precision Medicine and Systems Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
3
Faculty of Pharmacy, Silpakorn University, Nakhon Prathom 73000, Thailand
4
Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University, Nakhon Nayok 26120, Thailand
*
Author to whom correspondence should be addressed.
Nutrients 2024, 16(15), 2441; https://doi.org/10.3390/nu16152441
Submission received: 17 June 2024 / Revised: 24 July 2024 / Accepted: 24 July 2024 / Published: 26 July 2024
(This article belongs to the Special Issue Diet Quality, Cardiometabolic Risk and Diabetes)
Browse Figures
Review Reports Versions Notes

Abstract

:
Curcumin, derived from turmeric root, exhibits notable anti-inflammatory effects. These anti-inflammatory properties might also provide advantages in reducing cardiovascular complications, such as atherosclerosis. This study aimed to evaluate the efficacy of curcumin in reducing the risk of atherogenesis in obese patients with type 2 diabetes. The study employed a randomized, double-blind, placebo-controlled trial design with 227 participants diagnosed with type 2 diabetes. The parameters used to assess atherogenic risk reduction included pulse wave velocity and metabolic profiles, including low-density lipoprotein cholesterol and small dense low-density lipoprotein cholesterol. Measurements were recorded at baseline and at 3-, 6-, 9-, and 12-month intervals. After 12 months, participants receiving curcumin exhibited a significant reduction in pulse wave velocity (p < 0.001). This group showed significantly reduced levels of cardiometabolic risk biomarkers, including low-density lipoprotein cholesterol and small dense low-density lipoprotein cholesterol, all with p values less than 0.001. High-sensitivity C-reactive protein, interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha were also significantly lower in the curcumin group, with p values less than 0.001. The curcumin intervention significantly reduced pulse wave velocity and improved cardiometabolic risk profiles. These findings suggest that curcumin treatment may effectively reduce atherogenic risks in type 2 diabetes patients with obesity.

Graphical Abstract

1. Introduction

Type 2 diabetes mellitus (T2DM) is a persistent state of hyperglycemia and glucose intolerance caused by an inadequate response to insulin, followed by increased insulin production and subsequent insulin resistance. With significant impacts on global public health, T2DM ranks as one of the most common chronic diseases globally, with prevalence rates soaring, particularly among adults, due to lifestyle factors. The increasing prevalence is attributed to aging populations, urbanization, sedentary lifestyles, and poor dietary habits [1,2]. Beyond its primary association with insulin resistance, T2DM encompasses abnormal metabolic conditions, including abdominal obesity, dyslipidemia, hyperuricemia, hypertension, and cardiovascular complications.
Individuals with type 2 diabetes mellitus (T2DM) have a two- to four-times higher risk of developing cardiovascular diseases compared to those without diabetes [3]. Additionally, the prevalence of coronary heart disease in people with type 2 diabetes is about 21%, compared to 9.1% in those without diabetes [4].
Recent findings indicate that T2DM and insulin resistance are linked to cardiovascular conditions and contribute to atherogenesis [5,6,7]. This association is further elucidated through the activation of inflammatory pathways in T2DM patients, highlighting the significant role of the inflammatory milieu in the development of vascular complications and establishing the connection between diabetes mellitus and cardiovascular diseases, particularly atherosclerosis [7]. The levels of circulating pro-inflammatory cytokines, such as interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), which are elevated in T2DM patients, underscore the relationship between T2DM and inflammation in the pathogenesis of atherosclerosis [8,9]. Additionally, metabolic parameters that promote atherogenesis, including abdominal obesity (total body fat and visceral fat) [10,11] and high uric acid levels [12,13], are commonly found in patients with T2DM, adding layers of complexity to their risk profile.
Natural products are crucial in developing innovative treatments for metabolic diseases like diabetes, obesity, and cardiovascular disorders. Compounds such as curcumin target multiple metabolic pathways, offering the potential for comprehensive disease management with potentially fewer side effects. Their structural diversity provides a vast pool for drug discovery. These multi-target effects and historical usage underscore the importance of natural products in creating effective, holistic treatments for metabolic diseases [14].
Curcumin (Curcuma longa Linn.), the principal component of the spice turmeric, has recently garnered interest for its potential benefits in addressing various health conditions, notably metabolic syndrome [15]. Research has highlighted the antihypercholesterolemic properties of curcumin extract, including a reduction in cholesterol and triglyceride (TG) levels and decreased vulnerability to low-density lipoprotein cholesterol (LDL-C). The anti-atherosclerotic and protective effects of curcumin against coronary heart disease have also been recognized [16,17,18]. Additionally, curcumin has notable potential in managing metabolic diseases due to its anti-inflammatory, antioxidant, and lipid-modifying properties. It enhances insulin sensitivity and supports weight management. Curcumin also protects liver health and offers cardiovascular benefits by reducing inflammation and oxidative stress. These multifaceted effects make it a promising complementary therapy for conditions like obesity, type 2 diabetes, and cardiovascular diseases. Enhanced formulations improve its bioavailability, making curcumin an accessible option for metabolic disease management.
Inspired by these positive findings, we proposed a human trial of curcumin treatment for the prevention of arteriosclerosis.
Our previous research indicated that curcumin intervention is associated with decreases in TG, uric acid, visceral fat, and total body fat and contributes to attenuating cardiovascular risk factors in patients with T2DM [19]. Building on these findings, our current study aimed to investigate the efficacy and safety of curcumin extract as an intervention agent for reducing atherogenesis risk in obese T2DM patients. Specifically, this study focused on assessing the anti-inflammatory effects, improvements in cardiometabolic risk markers, and weight-management effects. An evidence-based, double-blind, placebo-controlled clinical trial was conducted to explore the potential of curcumin as an intervention agent for atherogenesis in T2DM patients.

2. Subjects and Methods

2.1. Study Design and Participants

This randomized, double-blind, placebo-controlled trial was conducted at HRH Princess Maha Chakri Sirindhorn Medical Center of Srinakharinwirot University in Nakhon Nayok, Thailand. Based on specific inclusion and exclusion criteria, we selected 227 patients with T2DM. Supplementary Figure S1 shows a CONSORT diagram of the patient flow.
Eligible subjects were ≥35 years old and diagnosed with T2DM during the previous year. All also had well-controlled glucose levels (glycated hemoglobin [HbA1c] < 6.5%), fasting plasma glucose (FPG) < 110 mg/dL), and a body mass index ≥ 23 kg/m2. Diabetes was diagnosed according to the American Diabetes Association guidelines of 2017 [20]. Specifically, at least one of the following criteria needed to be met: FPG ≥ 126 mg/dL, 2-h plasma glucose ≥ 200 mg/dL during an oral glucose tolerance test, HbA1c ≥ 6.5%, or random plasma glucose ≥ 200 mg/dL accompanied by classic symptoms of hyperglycemia or a hyperglycemic crisis.
The exclusion criteria included type 1 diabetes, impaired glucose tolerance, metabolic syndrome, maturity-onset diabetes of the young, and gestational diabetes. Those with hypertension or dyslipidemia received stable doses of the respective medications to manage their conditions. To ensure the changing of variable parameters such as blood glucose levels and lipid profiles due to curcumin effects, we maintained existing treatment regimens for hyperglycemia and dyslipidemia. These unchanged regimens served as controlled parameters in the study.
The study spanned 12 months, during which we required all participants to adhere to uniform diet and exercise protocols for the first 3 months after enrollment (the prerandomization phase). Before the study commenced, we provided participants with written lifestyle recommendations. We also conducted a 20- to 30-min individual workshop emphasizing the importance of maintaining a healthy lifestyle, including medical nutrition therapy and physical activity. Nutrient intake at baseline and at 12 weeks was estimated using Computer Dietary Guidance System Software (CDGSS 3.0) and was based on a 3-day food record (2 weekdays and 1 weekend). Further dietary habits were assessed through a questionnaire administered at baseline (Supplementary Table S1). However, we observed a relatively low daily calorie intake. This low-calorie intake could be due to an underestimation of dietary fiber consumption. Since dietary fiber is not fully digested and absorbed, it contributes fewer calories than other carbohydrates. Thus, underestimating fiber intake can lead to a seemingly lower total calorie count. Additionally, higher fiber intake increases satiety, which may reduce overall food consumption and further lower the reported calorie intake [21].
Throughout the trial, fasting overnight was mandatory before blood sample collection at 0, 3, 6, 9, and 12 months. Participants with an HbA1c ≥ 7.0% or an FPG ≥ 130 mg/dLL on two consecutive tests were excluded (Supplementary Figure S1). Any occurrence of uncontrolled hypertension (blood pressure ≥ 140/90 twice) or uncontrolled dyslipidemia (LDL-C ≥ 130 mg/dL twice) also led to exclusion.
The trial received approval from the Ethics Committee of the Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand (SWUEC/FB 4/2556, 22 February 2013), and it was registered with the Thai Clinical Trials Registry (TCTR20140303003). The research was conducted in accordance with the Declaration of Helsinki. All participants provided informed consent prior to enrollment.

2.2. Randomization Procedures

Participants were randomly allocated to either the curcumin-treated (intervention) group or the placebo-treated (control) group. The randomization was orchestrated using a fixed scheme based on computer-generated random numbers conducted by an independent researcher. The resulting assignment details were concealed within opaque, consecutively numbered envelopes that were sequentially opened by an independent party. Participants were made aware that the trial was comparing two distinct interventions.

2.3. Intervention

All participants were instructed to take three capsules of either curcumin or placebo in a double-blind manner. They were administered orally, twice daily, after meals (a total of six capsules per day) for 12 months. Each curcumin capsule contained 250 mg of curcuminoids. The curcumin and placebo capsules, which were identical in appearance, were manufactured by the Government Pharmaceutical Organization of Thailand to ensure uniformity. To assess adherence, participants were required to return all capsules at follow-up visits scheduled at 3, 6, 9, and 12 months. The number of capsules consumed by each subject was meticulously recorded (refer to Supplementary Table S2).

2.4. Preparation of Curcuminoid Capsules

Dried turmeric rhizomes (Curcuma longa Linn.), cultivated in Kanchanaburi Province, Thailand, were processed into a powder. The turmeric powder was subjected to ethanol extraction and evaporated under low pressure to produce a semisolid ethanol extract containing oleoresin and curcuminoids. The oleoresin was subsequently removed to isolate the curcuminoid extract, which had a total curcuminoid content ranging from 75% to 85%. The proportionate peak ratios of curcumin to demethoxycurcumin and bisdemethoxycurcumin within the extract were verified using high-performance thin-layer chromatography. This curcuminoid extract, which was calculated to contain 250 mg of curcuminoids, was then encapsulated under Good Manufacturing Practices standards. The detailed chemical composition and fingerprints of the extracts are shown in Supplementary Figure S2.

2.5. Study Outcomes

The study’s primary outcome focused on assessing antiatherogenic activities by measuring pulse wave velocity (PWV) in the curcumin-treated and placebo groups. High-sensitivity C-reactive protein levels were measured to evaluate systemic inflammation and predict potential cardiac events. Furthermore, changes in the levels of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) were meticulously recorded. Cardiometabolic risk factors, including total cholesterol, TG, LDL-C, small dense low-density lipoprotein cholesterol (sdLDL-C), and uric acid, were also monitored. Total body fat and visceral fat measurements were employed to assess abdominal obesity. Monitoring for adverse effects included observing elevations in creatinine levels ≥ 1.2 mg/dL and aspartate transaminase/alanine transaminase levels ≥ 3 times the upper limit of the normal range. Additionally, any symptoms reported by patients were thoroughly documented [22].

2.6. Data Collection and Measurement Methods

Measurements were conducted at baseline (prior to treatment) and at 3, 6, 9, and 12 months following the onset of the intervention. Demographic data were collected at baseline; researchers administered a questionnaire detailing medical history and medication use, and they measured body weight, height, waist circumference, and vital signs. Waist circumference, an indicator of abdominal obesity, was measured midway between the inferior margin of the rib and the superior border of the iliac crest using tape on the horizontal plane [23]. Abdominal obesity, further delineated by total body fat and visceral fat, was assessed through bio-electrical impedance analysis using a body fat analyzer (Omron HBF-362; Omron Healthcare Singapore Pte Ltd., Alexandra Technopark, Singapore) to obtain detailed analyses of body fat and visceral fat levels [24].
Blood samples were drawn at 8:00 AM from the antecubital vein of patients in a recumbent position following an overnight fast. Plasma samples for IL-1β, IL-6, and TNF-α assays were frozen and stored at −70 °C until analysis. Changes in cardiometabolic risk factors, including FPG, HbA1c, and uric acid, were measured using standard procedures over the one-year follow-up period. The homeostatic model assessment of insulin resistance (HOMA-IR) was calculated to evaluate changes in insulin resistance [25]. Plasma levels of LDL-C, sdLDL-C, high-density lipoprotein cholesterol (HDL-C), and TG were measured using diagnostic kits from Randox Laboratories Ltd. (Antrim, UK) and analyzed with an automated analyzer (spACE; Schiapparelli Biosystems Inc., Columbia, MD, USA). Apolipoprotein B levels were determined using a commercial immunoassay [26].
High-sensitivity C-reactive protein levels were quantified using a BNII Nephelometer Analyzer (Dade Behring Inc., Newark, DE, USA) with a latex-enhanced immunonephelometric assay, with a detection limit of 0.17 mg/L. Pro-inflammatory cytokine levels (IL-1β, IL-6, and TNF-α) were measured using a standard enzyme-linked immunosorbent assay according to the manufacturer’s protocol (Abcam, Cambridge, UK).
The peripheral PWV (baPWV), represented by volume waveforms for the brachium and ankle, was measured using an automated waveform analyzer (Colin VP-1000; Omron Healthcare, Kyoto, Japan), as previously described [27]. In brief, the analyzer recorded the electrocardiogram, phonocardiogram, and three pulse waves from the brachial and dorsalis pedis arteries. Signal detection was enhanced through the use of amplifier, filter, and isolation circuits. The intersecting tangent algorithm, which employs the least square mean method, was used to determine the upstroke points. Regional PWV values for the brachial and dorsalis pedis arteries were automatically calculated after collecting 10 s of data. For baPWV, the brachial–dorsalis pedis transit time was calculated by dividing the brachial–dorsalis pedis path length by the transit time. The path length was estimated as the linear distance from the sternal notch to the dorsalis pedis artery at the point of applanation.

2.7. Sample Size

The sample size for this study was estimated based on data from Chuengsamarn et al. [28] using a standard deviation of 160 to achieve a statistical power of 80% with an alpha error of 0.05. To show an effect on PWV levels, specifically a reduction of 60 cm/s, we determined that at least 113 subjects were needed in each treatment group to detect significant differences. After allowing for a potential 5% loss before follow-up, 227 subjects were deemed necessary across both groups. Equal group sizes were used to maximize the statistical power.

2.8. Statistical Analysis

Continuous data are presented as the means ± standard errors of the means, with a p value of <0.05 considered to indicate statistical significance. Two-tailed Student’s t tests were used for baseline comparisons and outcome evaluations between the two groups. Two-sided significance tests were consistently applied. The means ± standard errors of the means at 3, 6, 9, and 12 months are presented for both groups. All analyses were conducted on an intention-to-treat basis, assessing statistically significant differences between the means of the two groups at each time point. All comparisons were performed using paired samples t-test (for normally distributed data) or Wilcoxon signed-ranks test (for non-normally distributed data).
Categorical variables are expressed as percentages and were analyzed using the chi-square test. Outcome data on efficacy and safety included all randomized patients; they were analyzed according to their originally assigned treatment group and irrespective of the actual treatment received. Patients who lacked baseline information from their initial visit were excluded from the analysis. All the statistical analyses were performed using R software (version 4.1.2; R Foundation for Statistical Computing, Vienna, Austria).

3. Results

The flow of the trial is depicted in the CONSORT diagram in Supplementary Figure S1. A total of 227 subjects were initially enrolled and randomly allocated to either the intervention group or the control group. There were no statistically significant differences in any baseline parameters between the curcumin-treated and placebo-treated groups (Table 1).

3.1. Curcumin Treatment and PWV

The mean values of the PWV for both the right and left sides were significantly lower in the curcumin-treated group than in the placebo group at the 3-, 6-, 9-, and 12-month visits (Table 2). Figure 1A,B illustrates the baseline differences in these variables between the two groups.

3.2. Glycemic Control Outcomes

The means of diabetes-related blood chemistries, such as HbA1c and FPG, were significantly lower in the curcumin-treated group than in the placebo group at the 6-, 9-, and 12-month visits (Table 2). The differences from baseline for these variables between the two groups are depicted in Figure 1C,D.

3.3. Anthropometric Measurement Outcomes

The means of waist circumference, total body fat, and visceral fat were significantly lower in the curcumin-treated group than in the placebo group at the 6-, 9-, and 12-month visits (Table 2). The differences from baseline for these measurements between the two groups are shown in Supplementary Figure S3A–C.

3.4. Cardiometabolic Risk Outcomes

The analysis of lipid profiles revealed that the mean levels of LDL-C and sdLDL-C, both potent markers of inflammatory processes linked to cardiovascular disease, were significantly lower in the curcumin-treated group than in the placebo group across all visits at 3, 6, 9, and 12 months (Table 2, Supplementary Figure S3D,E). Similarly, the TG/HDL-C ratio, a recognized marker for assessing cardiovascular health and risk, was significantly lower in the curcumin-treated group during these periods (Table 2, Supplementary Figure S3F). Additionally, apolipoprotein B, which is associated with cardiovascular disease risk, was significantly reduced in the curcumin-treated group at the 6-, 9-, and 12-month visits (Table 2, Supplementary Figure S3G). Serum uric acid levels were also significantly lower in the curcumin-treated group than in the control group at all study visits (3, 6, 9, and 12 months; Table 2, Supplementary Figure S3H).

3.5. Insulin Resistance and Inflammatory Biomarker Outcomes

Insulin resistance, measured via HOMA-IR, was significantly lower in the curcumin-treated group than in the placebo group at all follow-up assessments (3, 6, 9, and 12 months; Supplementary Figure S3I). The levels of high-sensitivity C-reactive protein, an acute-phase protein indicative of systemic inflammation, significantly decreased across all follow-up visits in the curcumin-treated group (Table 2, Supplementary Figure S3J). Additionally, the levels of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α were significantly lower in the curcumin-treated group than in the placebo group at the 6-, 9-, and 12-month assessments (Table 2, Supplementary Figure S3K–M).

4. Discussion

Cardiovascular disease remains the leading cause of morbidity and mortality globally and is largely driven by atherosclerosis. This progressive disease is characterized by the accumulation of lipids, inflammatory cells, and fibrous elements in arterial walls, leading to narrowing and compromised blood flow [29]. T2DM is intricately linked with atherosclerosis and exacerbates this condition through mechanisms such as hyperglycemia, inflammation, and lipid abnormalities. These factors damage vascular walls, foster plaque buildup, and disrupt metabolic profiles, further accelerating the progression of atherosclerosis.
Curcumin is derived from turmeric root and is known for its cardiovascular protective effects [16]. Medical doctors prescribed curcumin or placebo capsules for three-month periods. We therefore investigated its potential as a safe and well-tolerated intervention to prevent atherosclerosis in T2DM patients with obesity in Thai people. According to the World Health Organization (WHO), obesity is defined as a body mass index (BMI) of 30.0 kg/m2 or higher for White people. For Asian people, obesity is defined as a BMI of 25.0 kg/m2 or higher [30,31]. This double-blind, placebo-controlled trial evaluated ethanol-extracted curcumin, an accessible nutraceutical, with subjects consuming 1500 mg/day. We employed PWV as a primary noninvasive metric to assess arterial stiffness and, by extension, atherosclerosis risk [32,33,34]. PWV is also recognized as a reliable surrogate marker for atherosclerosis and for monitoring the efficacy of atherogenic treatments [35]. Our findings indicate that curcumin significantly reduced the PWV, substantiating its role in mitigating arterial stiffness and potential cardiovascular disease risk [36].
Furthermore, this study explored various cardiometabolic risk parameters predisposing individuals to atherosclerosis. These comprised lipid profiles (LDL-C, sdLDL-C, apolipoprotein B, TG/HDL-C ratio), abdominal obesity (waist circumference, total body fat, and visceral fat), uric acid levels, and HOMA-IR. HOMA-IR is a clinical marker of insulin resistance that strongly correlates with atherosclerosis in patients with T2DM and metabolic syndrome [37,38]. Our previous research demonstrated significant improvements in these cardiometabolic risk parameters following curcumin treatment [19].
Curcumin treatment has demonstrated anti-inflammatory effects both in vitro and in vivo [39,40,41]. It decreases the levels of IL-1β [42,43], IL-6 [44,45], and TNF-α [46,47]. These pro-inflammatory cytokines play crucial roles in the pathogenesis of atherosclerosis by promoting inflammation, endothelial dysfunction, and plaque formation. Lowering these cytokine levels represents a potential therapeutic strategy for mitigating atherosclerotic cardiovascular diseases [48,49]. Our study revealed that a 6-month curcumin treatment significantly reduced IL-1β, IL-6, and TNF-α in type 2 diabetes patients with obesity.
Additionally, we found that high-sensitivity C-reactive protein, a marker associated with inflammation and cardiovascular risk [50,51,52], was reduced after 3 months of curcumin treatment. This reduction, along with improvements in other cardiometabolic risk factors (HOMA-IR, LDL-C, sdLDL-C, apolipoprotein B, TG/HDL-C ratio, uric acid, waist circumference, total body fat, and visceral fat), suggests a comprehensive cardiometabolic benefit. These changes may contribute to the reduction in PWV observed in this study by attenuating the inflammatory processes related to atherogenesis.
In terms of diabetes management, notable decreases in FPG and HbA1c were observed as early as 3 months into treatment, suggesting an antidiabetic effect of curcumin. Regarding safety, curcumin was well tolerated at the administered dose of 1500 mg/day, consistent with other studies showing safe consumption of much higher doses (up to 8000 mg/day) without any severe side effects [53]. However, our study has several limitations. Firstly, its single-dose design prevents us from analyzing potential dose–response relationships. Secondly, being a single-center randomized controlled trial, the findings may not be generalizable to other populations or settings.

5. Conclusions

Curcumin, a bioactive compound in turmeric, shows potential for reducing atherogenic risk by mitigating inflammation and improving cardiometabolic factors. These effects are promising for protecting against atherosclerosis and related cardiometabolic risks in type 2 diabetes patients with obesity. By reducing cardiometabolic risk factors, curcumin provides various health benefits, making it a valuable component of a balanced diet and healthy lifestyle. Future research should focus on optimizing its bioavailability for enhanced efficacy. We aim to broaden the findings through a multicenter randomized controlled trial.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu16152441/s1, Table S1: Mean Daily Intake of Nutrients by Subjects at Baseline and 12 Months in Placebo and Curcumin Groups; Figure S1: CONSORT Flow Diagram of Patient Enrollment, Allocation, Follow-Up, and Analysis; Figure S2: Fingerprints of Curcuminoid Extracts; Table S2: Number of Capsules Consumed by Subjects per 3 Months and per Day, Counted at the 3-, 6-, 9-, and 12-Month Visits; Table S3: Adverse Effects (Creatinine, AST, ALT) in Curcumin-Treated and Placebo-Treated Groups at Each Follow-Up Visit; Figure S3: Mean of parameters with SEM at baseline, 3, 6, 9 and 12 months were compared between placebo- and curcumin-treated group.

Author Contributions

Conceptualization, S.C.; Methodology, M.Y., L.J. and S.C.; Validation, M.Y.; Formal analysis, M.Y.; Investigation, M.Y., L.J. and S.C.; Resources, S.C.; Data curation, M.Y.and S.C.; Writing—original draft, M.Y.; Writing—review & editing, M.Y., S.J. and S.C.; Visualization, M.Y. and L.J.; Supervision, S.C.; Project administration, S.C.; Funding acquisition, S.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research was financially supported by joint funding between Thailand Research Fund (grant number 022/2012) and Thai Traditional Medical Knowledge Fund, Ministry of Public Health, Thailand (grant number 29/2013) (to S.C.).

Institutional Review Board Statement

The study was condfucted according to the guidelines of the Declaration of Helsinki, approved by Ethics Committee of the Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand (SWUEC/FB 4/2556, 22 February 2013) and registered with the Thai Clinical Trials Registry (TCTR20140303003).

Informed Consent Statement

All participants provided informed consent prior to enrollment.

Data Availability Statement

The original contributions presented in the study are included in the article/supplementary materials, further inquiries can be directed to the corresponding author.

Acknowledgments

The authors extend their gratitude to the Thai Government Pharmaceutical Organization for supplying the curcumin extract and placebo used in this study. Appreciation is also extended to all participants and the medical team at the outpatient clinic of HRH Princess Maha Chakri Sirindhorn Medical Center of Srinakharinwirot University, Nakhon Nayok, Thailand, for their contributions.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Magkos, F.; Yannakoulia, M.; Chan, J.L.; Mantzoros, C.S. Management of the metabolic syndrome and type 2 diabetes through lifestyle modification. Annu. Rev. Nutr. 2009, 29, 223–256. [Google Scholar] [CrossRef] [PubMed]
  2. DeFronzo, R.A.; Ferrannini, E.; Groop, L.; Henry, R.R.; Herman, W.H.; Holst, J.J.; Hu, F.B.; Kahn, C.R.; Raz, I.; Shulman, G.I. Type 2 diabetes mellitus. Nat. Rev. Dis. Prim. 2015, 1, 15019. [Google Scholar] [CrossRef] [PubMed]
  3. Care, D. Cardiovascular disease and risk management: Standards of medical care in diabetesd 2021. Diabetes Care 2021, 44, S125–S150. [Google Scholar]
  4. Beckman, J.A.; Creager, M.A.; Libby, P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA 2002, 287, 2570–2581. [Google Scholar] [CrossRef] [PubMed]
  5. Katakami, N. Mechanism of development of atherosclerosis and cardiovascular disease in diabetes mellitus. J. Atheroscler. Thromb. 2018, 25, 27–39. [Google Scholar] [CrossRef] [PubMed]
  6. Poznyak, A.; Grechko, A.V.; Poggio, P.; Myasoedova, V.A.; Alfieri, V.; Orekhov, A.N. The diabetes mellitus–atherosclerosis connection: The role of lipid and glucose metabolism and chronic inflammation. Int. J. Mol. Sci. 2020, 21, 1835. [Google Scholar] [CrossRef] [PubMed]
  7. Tsalamandris, S.; Antonopoulos, A.S.; Oikonomou, E.; Papamikroulis, G.-A.; Vogiatzi, G.; Papaioannou, S.; Deftereos, S.; Tousoulis, D. The role of inflammation in diabetes: Current concepts and future perspectives. Eur. Cardiol. Rev. 2019, 14, 50. [Google Scholar] [CrossRef] [PubMed]
  8. Banerjee, M.; Saxena, M. Interleukin-1 (IL-1) family of cytokines: Role in type 2 diabetes. Clin. Chim. Acta 2012, 413, 1163–1170. [Google Scholar] [CrossRef] [PubMed]
  9. Popko, K.; Gorska, E.; Stelmaszczyk-Emmel, A.; Plywaczewski, R.; Stoklosa, A.; Gorecka, D.; Pyrzak, B.; Demkow, U. Proinflammatory cytokines Il-6 and TNF-α and the development of inflammation in obese subjects. Eur. J. Med. Res. 2010, 15, 120–122. [Google Scholar] [CrossRef]
  10. Piché, M.-E.; Tchernof, A.; Després, J.-P. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ. Res. 2020, 126, 1477–1500. [Google Scholar] [CrossRef]
  11. Raheem, J.; Sliz, E.; Shin, J.; Holmes, M.V.; Pike, G.B.; Richer, L.; Gaudet, D.; Paus, T.; Pausova, Z. Visceral adiposity is associated with metabolic profiles predictive of type 2 diabetes and myocardial infarction. Commun. Med. 2022, 2, 81. [Google Scholar] [CrossRef] [PubMed]
  12. Hayden, M.R.; Tyagi, S.C. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr. Metab. 2004, 1, 10. [Google Scholar] [CrossRef] [PubMed]
  13. El Din, U.A.S.; Salem, M.M.; Abdulazim, D.O. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review. J. Adv. Res. 2017, 8, 537–548. [Google Scholar] [CrossRef] [PubMed]
  14. Harvey, A.L.; Edrada-Ebel, R.; Quinn, R.J. The re-emergence of natural products for drug discovery in the genomics era. Nat. Rev. Drug Discov. 2015, 14, 111–129. [Google Scholar] [CrossRef] [PubMed]
  15. Hewlings, S.J.; Kalman, D.S. Curcumin: A review of its effects on human health. Foods 2017, 6, 92. [Google Scholar] [CrossRef]
  16. Li, H.; Sureda, A.; Devkota, H.P.; Pittalà, V.; Barreca, D.; Silva, A.S.; Tewari, D.; Xu, S.; Nabavi, S.M. Curcumin, the golden spice in treating cardiovascular diseases. Biotechnol. Adv. 2020, 38, 107343. [Google Scholar] [CrossRef] [PubMed]
  17. Wang, R.; Zhang, J.-Y.; Zhang, M.; Zhai, M.-G.; Di, S.-Y.; Han, Q.-H.; Jia, Y.-P.; Sun, M.; Liang, H.-L. Curcumin attenuates IR-induced myocardial injury by activating SIRT3. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 1150–1160. [Google Scholar]
  18. Qin, S.; Huang, L.; Gong, J.; Shen, S.; Huang, J.; Ren, H.; Hu, H. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: A meta-analysis of randomized controlled trials. Nutr. J. 2017, 16, 68. [Google Scholar] [CrossRef] [PubMed]
  19. Chuengsamarn, S.; Rattanamongkolgul, S.; Phonrat, B.; Tungtrongchitr, R.; Jirawatnotai, S. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: A randomized controlled trial. J. Nutr. Biochem. 2014, 25, 144–150. [Google Scholar] [CrossRef]
  20. American Diabetes Association. Standards of medical care in diabetes—2017 abridged for primary care providers. Clin. Diabetes Publ. Am. Diabetes Assoc. 2017, 35, 5–26. [Google Scholar]
  21. Slavin, J.L. Dietary fiber and body weight. Nutrition 2005, 21, 411–418. [Google Scholar] [CrossRef]
  22. Chainani-Wu, N. Safety and anti-inflammatory activity of curcumin: A component of tumeric (Curcuma longa). J. Altern. Complement. Med. 2003, 9, 161–168. [Google Scholar] [CrossRef]
  23. Ross, R.; Neeland, I.J.; Yamashita, S.; Shai, I.; Seidell, J.; Magni, P.; Santos, R.D.; Arsenault, B.; Cuevas, A.; Hu, F.B. Waist circumference as a vital sign in clinical practice: A Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat. Rev. Endocrinol. 2020, 16, 177–189. [Google Scholar] [CrossRef] [PubMed]
  24. Bera, T.K. Bioelectrical impedance methods for noninvasive health monitoring: A review. J. Med. Eng. 2014, 2014, 381251. [Google Scholar] [CrossRef]
  25. Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.; Treacher, D.F.; Turner, R.C. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28, 412–419. [Google Scholar] [CrossRef] [PubMed]
  26. Kulkarni, K. Apo B Measurement System and Method. U.S. Patent US20080261313A1, 17 April 2008. [Google Scholar]
  27. Svačinová, J.; Hrušková, J.; Jakubík, J.; Budinskaya, K.; Hidegová, S.; Fabšík, M.; Sieglová, H.; Kaščáková, Z.; Novák, J.; Nováková, Z. Variability of peripheral pulse wave velocity in patients with diabetes mellitus type 2 during orthostatic challenge. Physiol. Res. 2020, 69 (Suppl. S3), S433. [Google Scholar] [CrossRef]
  28. Chuengsamarn, S.; Rattanamongkolgul, S.; Jirawatnotai, S. Association between serum uric acid level and microalbuminuria to chronic vascular complications in Thai patients with type 2 diabetes. J. Diabetes Complicat. 2014, 28, 124–129. [Google Scholar] [CrossRef]
  29. Lnsis, A. Atherosclenrosis. Nature 2000, 407, 233–241. [Google Scholar]
  30. WHO Consultation on Obesity. Obesity: Preventing and Managing the Global Epidemic; World Health Organization technical report series; WHO: Geneva, Switzerland, 2000; Volume 894, pp. 1–253.
  31. World Health Organization. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment; Health Communications Australia: Sydney, Australia, 2000.
  32. Zieman, S.J.; Melenovsky, V.; Kass, D.A. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 932–943. [Google Scholar] [CrossRef]
  33. Palombo, C.; Kozakova, M. Arterial stiffness, atherosclerosis and cardiovascular risk: Pathophysiologic mechanisms and emerging clinical indications. Vasc. Pharmacol. 2016, 77, 1–7. [Google Scholar] [CrossRef]
  34. Intengan, H.D.; Schiffrin, E.L. Vascular remodeling in hypertension: Roles of apoptosis, inflammation, and fibrosis. Hypertension 2001, 38, 581–587. [Google Scholar] [CrossRef] [PubMed]
  35. Blacher, J.; Asmar, R.; Djane, S.; London, G.M.; Safar, M.E. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999, 33, 1111–1117. [Google Scholar] [CrossRef] [PubMed]
  36. Mancia, G.; Kreutz, R.; Brunström, M.; Burnier, M.; Grassi, G.; Januszewicz, A.; Muiesan, M.L.; Tsioufis, K.; Agabiti-Rosei, E.; Algharably, E.A.E. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J. Hypertens. 2023, 41, 1874–2071. [Google Scholar] [PubMed]
  37. Ishizaka, N.; Ishizaka, Y.; Takahashi, E.; Unuma, T.; Tooda, E.-I.; Nagai, R.; Togo, M.; Tsukamoto, K.; Hashimoto, H.; Yamakado, M. Association between Insulin Resistance and Carotid Arteriosclerosis in Subjects with Normal Fasting Glucose and Normal Glucose Tolerance. Arteriosc. Thromb. Vasc. Biol. 2003, 23, 295–301. [Google Scholar] [CrossRef] [PubMed]
  38. Gast, K.B.; Tjeerdema, N.; Stijnen, T.; Smit, J.W.A.; Dekkers, O.M. Insulin Resistance and Risk of Incident Cardiovascular Events in Adults without Diabetes: Meta-Analysis. PLoS ONE 2012, 7, e52036. [Google Scholar] [CrossRef] [PubMed]
  39. Venkata, M.; Sripathy, R.; Anjana, D.; Somashekara, N.; Krishnaraju, A.; Krishanu, S.; Murali, M.; Verma, S.R.; Ramchand, C. In silico, in vitro and in vivo assessment of safety and anti-inflammatory activity of curcumin. Am. J. Infect. Dis. 2012, 8, 26. [Google Scholar]
  40. Jiang, S.; Han, J.; Li, T.; Xin, Z.; Ma, Z.; Di, W.; Hu, W.; Gong, B.; Di, S.; Wang, D.; et al. Curcumin as a potential protective compound against cardiac diseases. Pharmacol. Res. 2017, 119, 373–383. [Google Scholar] [CrossRef] [PubMed]
  41. Shehzad, A.; Rehman, G.; Lee, Y.S. Curcumin in inflammatory diseases. BioFactors 2013, 39, 69–77. [Google Scholar] [CrossRef] [PubMed]
  42. Zhang, S.; Zou, J.; Li, P.; Zheng, X.; Feng, D. Curcumin Protects against Atherosclerosis in Apolipoprotein E-Knockout Mice by Inhibiting Toll-like Receptor 4 Expression. J. Agric. Food Chem. 2018, 66, 449–456. [Google Scholar] [CrossRef]
  43. Merhi-Soussi, F.; Kwak, B.R.; Magne, D.; Chadjichristos, C.; Berti, M.; Pelli, G.; James, R.W.; Mach, F.; Gabay, C. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc. Res. 2005, 66, 583–593. [Google Scholar] [CrossRef]
  44. Madan, M.; Bishayi, B.; Hoge, M.; Amar, S. Atheroprotective role of interleukin-6 in diet- and/or pathogen-associated atherosclerosis using an ApoE heterozygote murine model. Atherosclerosis 2008, 197, 504–514. [Google Scholar] [CrossRef] [PubMed]
  45. Schieffer, B.; Schieffer, E.; Hilfiker-Kleiner, D.; Hilfiker, A.; Kovanen, P.T.; Kaartinen, M.; Nussberger, J.; Harringer, W.; Drexler, H. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque instability. Circulation 2000, 101, 1372–1378. [Google Scholar] [CrossRef] [PubMed]
  46. Brånén, L.; Hovgaard, L.; Nitulescu, M.; Bengtsson, E.; Nilsson, J.; Jovinge, S. Inhibition of Tumor Necrosis Factor-α Reduces Atherosclerosis in Apolipoprotein E Knockout Mice. Arteriosc. Thromb. Vasc. Biol. 2004, 24, 2137–2142. [Google Scholar] [CrossRef] [PubMed]
  47. Zhang, Y.; Yang, X.; Bian, F.; Wu, P.; Xing, S.; Xu, G.; Li, W.; Chi, J.; Ouyang, C.; Zheng, T.; et al. TNF-α promotes early atherosclerosis by increasing transcytosis of LDL across endothelial cells: Crosstalk between NF-κB and PPAR-γ. J. Mol. Cell. Cardiol. 2014, 72, 85–94. [Google Scholar] [CrossRef] [PubMed]
  48. Tousoulis, D.; Oikonomou, E.; Economou, E.K.; Crea, F.; Kaski, J.C. Inflammatory cytokines in atherosclerosis: Current therapeutic approaches. Eur. Heart J. 2016, 37, 1723–1732. [Google Scholar] [CrossRef] [PubMed]
  49. Fatkhullina, A.R.; Peshkova, I.O.; Koltsova, E.K. The Role of Cytokines in the Development of Atherosclerosis. Biochemistry 2016, 81, 1358–1370. [Google Scholar] [CrossRef]
  50. Yu, H.; Rifai, N. High-Sensitivity C-Reactive Protein and Atherosclerosis: From Theory to Therapy. Clin. Biochem. 2000, 33, 601–610. [Google Scholar] [CrossRef]
  51. Libby, P.; Ridker, P.M. Inflammation and atherosclerosis: Role of C-Reactive protein in risk assessment. Am. J. Med. 2004, 116 (Suppl. S6A), 9–16. [Google Scholar] [CrossRef]
  52. Tang, M.; Cao, H.; Wei, X.H.; Zhen, Q.; Liu, F.; Wang, Y.F.; Fan, N.G.; Peng, Y.D. Association between High-Sensitivity C-Reactive Protein and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus. Front. Endocrinol. 2022, 13, 885516. [Google Scholar] [CrossRef]
  53. Hsieh, C. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21, e2900. [Google Scholar]
Nutrients 16 02441 g001aNutrients 16 02441 g001b
Figure 1. Mean of parameters with SEM at baseline, 3, 6, 9 and 12 months were compared between placebo- and curcumin-treated group. (A) Pulse wave velocity right; (B) Pulse wave velocity left; (C) Glycated hemoglobin (HbA 1c); (D) Fasting plasma glucose. * Statistically significant.
Figure 1. Mean of parameters with SEM at baseline, 3, 6, 9 and 12 months were compared between placebo- and curcumin-treated group. (A) Pulse wave velocity right; (B) Pulse wave velocity left; (C) Glycated hemoglobin (HbA 1c); (D) Fasting plasma glucose. * Statistically significant.
Nutrients 16 02441 g001aNutrients 16 02441 g001b
Table 1. Baseline Characteristics of Study Participants.
Table 1. Baseline Characteristics of Study Participants.
VariablesPlaceboCurcuminp *
Mean (S.E.)
(n = 114)		Mean (S.E.)
(n = 113)
Sex ratio (Males:Females)54/80 (0.67)62/73 (0.85)0.87 ⵜ
Age (years)62.26 (0.81)60.27(0.83)0.13
BMI (kg/m2)26.76 (0.38)27.21 (0.37)0.41
Systolic blood pressure (mmHg)129.25(1.28)129.76 (1.30)0.95
Diastolic blood pressure (mmHg)75.84 (1.05)75.14 (1.15)0.95
Pulse wave velocity Rt (cm/s)1758.38 (35.26)1812.84 (29.27)0.26
Pulse wave velocity Lt (cm/s)1746.13 (36.10)1742.66 (28.40)0.08
Total body fat (%)33.21 (0.52)32.66 (0.59)0.58
Visceral fat (%)13.27 (0.49)13.89 (0.52)0.30
Waist circumference (cm)93.61(0.96)91.97 (10.87)0.30
FPG (mg/dl)125.80 (2.22)123.65 (1.73)0.40
HbA1c (%)6.26 (0.06)6.28 (0.07)0.69
HOMA-IR 5.24 (0.24)5.38 (0.23)0.72
TG/HDL-C ratio2.59 (0.15)2.53(0.16)0.25
LDL-C (mg/dL)103.91 (2.82)103.10 (3.04)0.60
sdLDL-C (mg/dL)36.54 (1.66)36.70 (1.64)0.55
ApoB (mg/dL)85.33 (1.67)84.06 (1.23)0.91
Uric acid (mg/dL)5.89 (0.12)6.07 (0.12)0.11
hs-CRP (mg/LL)2.98 (0.52)3.41(0.21)0.58
Interleukin-1 beta (pg/mL)0.44 (0.02)0.42 (0.02)0.46
Interleukin-6 (pg/mL)8.71 (0.11)8.96 (0.12)0.34
TNF-α (pg/mL)5.01 (0.14)4.78 (0.13)0.24
Creatinine (mg/dL)0.87 (0.02)0.86 (0.02)0.77
AST (U/L)25.01 (0.87)25.34 (0.80)0.58
ALT (U/L)27.58 (1.56)30.09 (1.50)0.08
History of cerebrovascular disease7 (5.2%)5 (3.7%)0.30 ⵜ
History of coronary artery disease9 (6.7%)8 (5.9%)0.80 ⵜ
History of hypertension82 (61.2%)76 (51.2%)0.68 ⵜ
History of dyslipidemia104 (77.6%)101 (74.8%)0.84 ⵜ
Abbreviations: FPG, fasting plasma glucose; ApoB, apolipoprotein B; ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; Lt, left; Rt, right; sdLDL-C, small dense low-density lipoprotein cholesterol; TG, triglyceride; TNF-α, tumor necrosis factor-alpha. * Data were evaluated using the Mann–Whitney U test, except for sex (M:F ratio). ⵜ Chi-square test.
Table 2. Cardiometabolic and Inflammatory Outcomes Over a 12-Month Follow-Up Period for the Placebo- and Curcumin-Treated Groups.
Table 2. Cardiometabolic and Inflammatory Outcomes Over a 12-Month Follow-Up Period for the Placebo- and Curcumin-Treated Groups.
OutcomesFollow-Up
Period
(Months)		PlaceboCurcuminp
MeanMinimum–MaximumMeanMinimum–Maximum
PWV Rt (cm/s)01758.381074–31211812.841123–2803NS
31780.35728–29151753.571082–3101<0.05
61777.31950–30121692.961145–2806<0.05
91780.391122–28191650.041097–2527<0.01
121773.591089–31281620.20789–2966<0.001
PWV Lt (cm/s)01746.13760–30431742.661240–2768NS
31765.701064–32041686.391066–3027<0.05
61763.351079–31141647.391092–3010<0.05
91770.711195–31311628.271134–2542<0.01
121783.171021–29171572.401023–3055<0.001
HbA1c (%)06.264.80–8.906.284.40–9.50NS
36.445.00–8.906.264.70–9.20<0.01
66.465.10–9.006.254.50–8.30<0.01
96.475.00–10.406.194.10–8.20<0.05
126.475.00–10.506.124.20–8.40<0.05
FPG (mg/dL)0125.0891–285123.6579–178NS
3128.93100–195124.4080–171NS
6130.3477–231122.8279–204<0.01
9130.9397–201118.6775–165<0.01
12130.7198–194115.4970–160<0.05
Waist circumference (cm)093.6161–12891.9771–120<0.05
393.8762–12891.0.170–118<0.001
693.9963–16590.4469–135<0.001
994.8163–12989.3968–117<0.001
1295.4663–14088.7068–114<0.001
Total body fat (%)033.2114.40–46.1032.6614.40–45.30NS
333.5016.80–46.2032.4514.20–45.80<0.05
634.1016.20–47.1031.4113.80–43.20<0.01
934.5419.00–47.4031.3413.60–46.40<0.001
1235.0421.00–48.1031.0213.40–46.10<0.001
Visceral fat (%)013.272.00–16.7513.894.00–30.00NS
313.213.00–31.0013.333.00–29.00<0.05
613.663.00–33.0012.282.00–28.00<0.01
913.793.00–35.0011.902.00–28.00<0.01
1213.723.00–36.0011.403.00–30.00<0.01
LDL-C (mg/dL)0102.6453–210103.1043.00–224.00NS
3103.5549–20192.5547.00–183.00<0.01
6104.9943–21590.9653.00–235.00<0.001
9105.2237–17987.2839.00–224.00<0.001
12105.9845–19386.7741.00–169.00<0.001
sdLDL-C (mg/dL)036.547.28–100.0036.708.34–96.52NS
339.527.07–99.0233.145.69–100.00<0.01
639.8111.10–99.0230.147.48–84.69<0.01
939.963.29–87.0527.112.62–60.59<0.001
1239.985.68–85.2221.652.62–63.65<0.001
TG/HDL-C ratio02.590.09–2.982.530.20–1.99NS
33.200.29–2.392.280.16–2.54<0.01
63.530.26–2.462.260.20–2.51<0.001
93.670.33–2.302.180.18–2.55<0.001
123.720.27–2.512.120.17–2.54<0.001
ApoB (mg/dL)084.3335–15384.0635.00–120.00NS
384.3036–15378.5435–132<0.05
6 months84.6734–15060.6829–105<0.001
9 months84.6633–15051.5121–85<0.001
12 months84.6638–15341.3520–78<0.001
Uric acid (mg/dL)0 months5.823.03–10.755.992.31–10.25NS
3 months6.022.74–9.415.872.72–11.13<0.05
6 months6.583.76–11.435.952.59–9.99<0.01
9 months6.543.40–10.615.472.71–9.21<0.001
12 months6.563.23–10.785.052.32–8.76<0.001
HOMA-IR0 months5.241.70–21.805.381.20–14.20NS
3 months5.882–175.251.70–12.80<0.05
6 months5.931.80–17.905.171.60–16.50<0.05
9 months6.022.20–19.805.021.30–11.50<0.05
12 months6.042.30–18.004.861.20–11.00<0.05
hs-CRP (mg/L)0 months3.410.20–44.492.980.22–16.64NS
3 months3.510.17–14.102.940.29–12.52<0.05
6 months3.530.26–29.812.810.26–19.25<0.05
9 months3.680.31–36.642.690.19–44.75<0.001
12 months3.750.25–30.242.600.14–14.60<0.001
Interleukin-1β (pg/mL)0 months0.440.01–0.860.460.01–0.88NS
3 months0.460.02–0.870.450.01–0.87NS
6 months0.710.20–1.740.430.15–1.54<0.001
9 months0.720.20–1.650.410.12–0.99<0.001
12 months0740.32–1.860.310.10–1.39<0.001
Interleukin-6 (pg/mL)0 months8.717.04–10.568.967.04–10.56NS
3 months8.897.04–10.568.727.04–10.56NS
6 months12.845.21–17.997.543.11–14.99<0.001
9 months14.307.65–19.666.823.2–13.24<0.001
12 months15.844.33–19.666.123.09–12.40<0.001
TNF-α (pg/mL)0 months5.012.64–7.044.772.64–7.04NS
3 months5.162.64–7.044.842.64–7.04NS
6 months5.912.18–14.884.231.46–10.5<0.001
9 months6.372.24–14.983.811.43–9.44<0.001
12 months6.772.14–15.373.461.33–8.59<0.001
Abbreviations: FPG, fasting plasma glucose; ApoB, apolipoprotein B; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; Lt, left; NS, not statistically significant; PWV, pulse wave velocity; Rt, right; sdLDL-C, small dense low-density lipoprotein cholesterol; TG, triglyceride; TNF-α, tumor necrosis factor-alpha.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Yaikwawong, M.; Jansarikit, L.; Jirawatnotai, S.; Chuengsamarn, S. The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial. Nutrients 2024, 16, 2441. https://doi.org/10.3390/nu16152441

AMA Style

Yaikwawong M, Jansarikit L, Jirawatnotai S, Chuengsamarn S. The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial. Nutrients. 2024; 16(15):2441. https://doi.org/10.3390/nu16152441

Chicago/Turabian Style

Yaikwawong, Metha, Laddawan Jansarikit, Siwanon Jirawatnotai, and Somlak Chuengsamarn. 2024. "The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial" Nutrients 16, no. 15: 2441. https://doi.org/10.3390/nu16152441

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop